Medical Oncology Prof. Dr. Özge Gümüşay
✓ Medically verified profileProf. Dr. Özge Gümüşay
✓ Medically verified profile
About Prof. Dr. Özge Gümüşay
Quick answer
Prof. Dr. Özge Gümüşay is a Medical Oncology specialist at Acibadem Atasehir Hospital in İstanbul with over 20 years of experience.
She treats breast cancer, including metastatic and triple-negative disease, as well as gastric cancer, and handles chemotherapy, targeted cancer therapy, cancer immunotherapy, CDK4/6 inhibitor therapy, pembrolizumab therapy, immunotherapy toxicity management, and liquid biopsy in breast cancer. She offers consultations in Turkish and English, including online video consultation.
Prof. Özge Gümüşay is a clinical oncology professor affiliated with Acibadem University Faculty of Medicine. Appointed to the professorship in 2023, she brings advanced medical training and leadership to her clinical and academic roles. Since 2022 she has been associated with Acibadem Health Group, contributing to patient care, multidisciplinary collaboration, and medical education.
She is an active member of leading oncology organizations, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Turkish Society of Medical Oncology (TTOD). Her membership in these societies reflects a commitment to evidence-based practice, staying current with global advances in cancer treatment, and participating in the international oncology community. Known for combining clinical expertise with teaching and research, Prof. Gümüşay focuses on delivering high-quality patient care while mentoring the next generation of physicians and engaging in professional development within national and international oncology networks.
Areas of Expertise
Conditions treated and procedures performed by this specialist.
Education
- 2023Acibadem University Faculty of Medicine / Professor
- 2022Acibadem University Faculty of Medicine/ Associate Professor
- 2017Gaziosmanpaşa University Faculty of Medicine/ Associate Professor
- 2014Gazi University Faculty of Medicine Medical Oncology
- 2010Gazi University Faculty of Medicine Internal Medicine
- 2005Hacettepe University Faculty of Medicine
Professional Experience
- 2022Acibadem Health Group
- 2021Stanford University Comprehensive Cancer Center, Palo Alto, California, (Visiting Observer)
- 2019–2021UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, (Breast Cancer Oncology)
- 2017–2019Gaziosmanpaşa University Faculty of Medicine, Medical Oncology Specialist, Associate Professor
- 2014–2017Gaziosmanpaşa University Faculty of Medicine, Medical Oncology Specialist, Assistant Professor
- 2010–2014Gazi University Faculty of Medicine, Medical Oncology Subspecialty Research Assistant
- 2006–2010Gazi University Faculty of Medicine, Internal Medicine Research Assistant
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- The European Society of Medical Oncology (ESMO)
- Turkish Society of Medical Oncology (TTOD)
Selected Publications
- CDK4/6 inhibitors: Mechanisms of resistance and potential biomarkers of responsiveness in breast cancer Future Oncology, 2022 Mar;18(9):1143-1157. Cetin B, Wabl CA, Gumusay O.
- Immunotherapy Toxicity: identification and management Breast Cancer Res Treat 2022 Feb;192(1):1-17. Gumusay O, Callan J, Rugo HS.
- Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Front. Oncol., March 15, 2022. (share first authorship) Magbanua MJ, Gumusay O, Kurzrock R, vant Veer LJ, Rugo HS.
- The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases Breast. 2022 Apr 2;63:149-156. Gumusay O, Huppert LA, Behr SC, Rugo HS.
- Emerging treatment strategies for metastatic triple-negative breast cancer. Therapeutic Advances in Medical Oncology. January 2022. Huppert LA, Gumusay O, Rugo HS.
- Trials of Immunotherapy in Triple Negative Breast Cancer. Curr Breast Cancer Rep 13, 171185 (2021). Gumusay O, Wabl, CA, Rugo HS.
- Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020 Jun 25;382(26): e108. Cetin B, Gumusay O.
- Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. Am Soc Clin Oncol Educ Book. 2020 May;40:e292-e308. Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS.
- Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients J Cancer Educ. 2016 Jun;31(2):308-13. Gumusay O, Cetin B, Benekli M, Gurcan G, Ilhan MN, Bostankolu B, Ozet A, Uner A, Coskun U, Buyukberber S.
- Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites Japanese Journal of Clinical Oncology. 2015 May; 45(5), 416-421. Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S.
Frequently Asked Questions
What is Dr. Özge Gümüşay's specialty?
Which hospital does Dr. Özge Gümüşay practise at?
What languages can I use when consulting Dr. Özge Gümüşay?
How can I book an appointment with Dr. Özge Gümüşay?
Is an online video consultation available with Dr. Özge Gümüşay?
How many years of experience does Dr. Özge Gümüşay have?
Can international patients arrange treatment with Dr. Özge Gümüşay?
How do I get a second opinion involving Dr. Özge Gümüşay?
A dedicated team, from first message to follow-up
Our international patient office coordinates your appointment, travel and treatment at JCI-accredited Acıbadem hospitals — and stays with you in your own language, every step of the way.
Schedule your appointment with Prof. Dr. Özge Gümüşay
Choose a date and time that suits you. Our international patient team will check availability and confirm your appointment — usually within 24 hours.
- 1Choose your date & timePick a preferred day and time slot for your visit.
- 2Share your detailsTell us how to reach you and anything we should know.
- 3We confirm with youOur team confirms the appointment by phone or email.
Request your appointment
This request goes directly to this doctor’s schedule.
Your information stays strictly confidential and is used only to arrange your care.

